Detalhe da pesquisa
1.
Engineered Human Antibody with Improved Endothelin Receptor Type A Binding Affinity, Developability, and Serum Persistence Exhibits Excellent Antitumor Potency.
Mol Pharm
; 20(2): 1247-1255, 2023 02 06.
Artigo
Inglês
| MEDLINE | ID: mdl-36563318
2.
Glycan-Controlled Human PD-1 Variants Displaying Broad-Spectrum High Binding to PD-1 Ligands Potentiate T Cell.
Mol Pharm
; 20(4): 2170-2180, 2023 04 03.
Artigo
Inglês
| MEDLINE | ID: mdl-36897183
3.
Selection and Characterization of YKL-40-Targeting Monoclonal Antibodies from Human Synthetic Fab Phage Display Libraries.
Int J Mol Sci
; 21(17)2020 Sep 01.
Artigo
Inglês
| MEDLINE | ID: mdl-32883029
4.
Effective clearance of rituximab-resistant tumor cells by breaking the mirror-symmetry of immunoglobulin G and simultaneous binding to CD55 and CD20.
Sci Rep
; 13(1): 18275, 2023 10 25.
Artigo
Inglês
| MEDLINE | ID: mdl-37880350
5.
A human antibody against human endothelin receptor type A that exhibits antitumor potency.
Exp Mol Med
; 53(9): 1437-1448, 2021 09.
Artigo
Inglês
| MEDLINE | ID: mdl-34588605
6.
Validation of Rapi-Fluor method for glycan profiling and application to commercial antibody drugs.
Talanta
; 198: 105-110, 2019 Jun 01.
Artigo
Inglês
| MEDLINE | ID: mdl-30876537
7.
Optimal combination of beneficial mutations for improved ADCC effector function of aglycosylated antibodies.
Mol Immunol
; 114: 62-71, 2019 10.
Artigo
Inglês
| MEDLINE | ID: mdl-31336250